miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
// Nicola Amodio 1 , Marco Rossi 1 , Lavinia Raimondi 2 , Maria Rita Pitari 1 , Cirino Botta 1 , Pierosandro Tagliaferri 1 and Pierfrancesco Tassone 1,3 1 Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy 2 Laboratory of Tissue Engineering-Innovative Technology Platforms for Tissue Engineering (PON01-00829), Rizzoli Orthopedic Institute, Palermo, Italy 3 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA Correspondence to: Pierfrancesco Tassone, email: // Keywords : miR-29a, miR-29b, miR-29c, hematologic malignancies, multiple myeloma Received : February 15, 2015 Accepted : March 18, 2015 Published : April 12, 2015 Abstract A wealth of studies has highlighted the biological complexity of hematologic malignancies and the role of dysregulated signal transduction pathways. Along with the crucial role of genetic abnormalities, epigenetic aberrations are nowadays emerging as relevant players in cancer development, and significant research efforts are currently focusing on mechanisms by which histone post-translational modifications, DNA methylation and noncoding RNAs contribute to the pathobiology of cancer. As a consequence, these studies have provided the rationale for the development of epigenetic drugs, such as histone deacetylase inhibitors and demethylating compounds, some of which are currently in advanced phase of pre-clinical investigation or in clinical trials. In addition, a more recent body of evidence indicates that microRNAs (miRNAs) might target effectors of the epigenetic machinery, which are aberrantly expressed or active in cancers, thus reverting those epigenetic abnormalities driving tumor initiation and progression. This review will focus on the broad epigenetic activity triggered by members of the miR-29 family, which underlines the potential of miR-29s as candidate epi-therapeutics for the treatment of hematologic malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
Identification of Novel Genes Coding for Small Expressed RNAs
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001) · Science · doi:10.1126/science.1064921 · Cited by 4,956
Non-coding RNAs in human disease
Esteller, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3074 · Cited by 4,825 · cited 1×
“A number of epigenetic modifications have been so far characterized, and among these, post-translational modification of histones [8], DNA methylation [9, 10] and the most recently discovered non-coding RNAs [11] are currently acknowledged as key determinants in the pathogenesis of human cancer, generally because aber…”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040 · cited 1×
“Protein acetylation regulates several functions including DNA-binding, activity of transcription factors, subcellular localization and protein stability [216].”
BackgroundIdentification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355 · cited 1×
“MiR-29a was initially detected in HeLa cells by Lagos-Quintana [89], followed by the subsequent discovery of miR-29b and miR-29c [90, 91].”
BackgroundHistone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 1×
“Nevertheless, increasing knowledge in cancer epigenetics [4], as well as the availability of experimental tools to study epigenetic modifications [5], suggest that epigenetic alterations are also involved in the development of human cancer [6].”
BackgroundHistone methylation: a dynamic mark in health, disease and inheritance
Greer, E. L., & Shi, Y. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3173 · Cited by 2,241 · cited 1×
“Histone methylation is reversible as evidenced by the discovery of histone demethylases , such as lysine specific demethylases (KMD1-5, also known as LSD-1) and JumonjiC (JmjC)-domain containing demethylases [220].”
BackgroundEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 1×
“The S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNeP) is an EZH2 inhibitor which promotes apoptosis by inducing degradation of EZH2 and consequent reduced levels of H3K27me levels [222].”
BackgroundSempere, L. F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., & Ambros, V. (2004) · Genome Biology · doi:10.1186/gb-2004-5-3-r13 · Cited by 1,578
Cited by
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
Amodio, N., Raimondi, L., Juli, G., Stamato, M. A., Caracciolo, D., Tagliaferri, P., & Tassone, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0606-4 · Cited by 348
Self-citationMicroenvironment drug resistance in multiple myeloma: emerging new players
Di Marzo, L., Desantis, V., Solimando, A. G., Ruggieri, S., Annese, T., Nico, B., Fumarulo, R., Vacca, A., & Frassanito, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.10849 · Cited by 173
Interplay between the miRNome and the epigenetic machinery: Implications in health and disease
Poddar, S., Kesharwani, D., & Datta, M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25819 · Cited by 57
Neaga, A., Bagacean, C., Tempescul, A., Jimbu, L., Mesaros, O., Blag, C., Tomuleasa, C., Bocsan, C., Gaman, M., & Zdrenghea, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582915 · Cited by 30
“miR-29a, miR-29b, and miR-29c were downregulated in PBMCs and bone marrow CD34 cells in AML patients as opposed to healthy donors (33, 42, 74, 75) miR29b targeted DNA methyltransferases (DNMTs) DNMT3A and DNMT3B, by reducing the global DNAmethylation and specificity protein (SP)1) and DNMT1, by targeting SP1 and enhan…”
BackgroundNon-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
Raimondi, L., De Luca, A., Giavaresi, G., Raimondo, S., Gallo, A., Taiana, E., Alessandro, R., Rossi, M., Neri, A., Viglietto, G., et al. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030037 · Cited by 16
Self-citation
Metadata
- Authors
- Amodio, N., Rossi, M., Raimondi, L., Pitari, M. R., Botta, C., Tagliaferri, P., & Tassone, P.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-04-12
- Volume
- 6
- Issue
- 15
- Pages
- 12837-12861
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1557393941
- Cited by
- 120
- References
- 20
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. https://app.cochat.ai/papers/10.18632/oncotarget.3805
- The paper
- Amodio, N., Rossi, M., Raimondi, L., Pitari, M. R., Botta, C., Tagliaferri, P., & Tassone, P. (2015). miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget. https://doi.org/10.18632/oncotarget.3805
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.